Syndax Pharmaceuticals Inc SNDX
We take great care to ensure that the data presented and summarized in this overview for Syndax Pharmaceuticals Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SNDX
View all-
Black Rock Inc. New York, NY7.91MShares$127 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.84MShares$94.1 Million9.23% of portfolio
-
Wellington Management Group LLP Boston, MA4.99MShares$80.3 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.89MShares$78.7 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.11MShares$66.1 Million6.25% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.89MShares$62.6 Million1.13% of portfolio
-
State Street Corp Boston, MA3.77MShares$60.7 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.78MShares$44.8 Million0.15% of portfolio
-
Avidity Partners Management LP Dallas, TX2.46MShares$39.6 Million2.9% of portfolio
-
Geode Capital Management, LLC Boston, MA1.98MShares$31.9 Million0.0% of portfolio
Latest Institutional Activity in SNDX
Top Purchases
Top Sells
About SNDX
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
Insider Transactions at SNDX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 14
2024
|
Keith A. Goldan Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,250
+2.32%
|
$25,000
$20.03 P/Share
|
|
Feb 07
2024
|
Jennifer Jarrett |
BUY
Grant, award, or other acquisition
|
Direct |
17,000
+20.73%
|
-
|
|
Feb 07
2024
|
Martin H. Huber Jr. |
BUY
Grant, award, or other acquisition
|
Direct |
17,000
+25.76%
|
-
|
|
Feb 07
2024
|
Neil Gallagher President, Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
47,813
+35.77%
|
-
|
|
Feb 07
2024
|
Keith A. Goldan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,700
+32.71%
|
-
|
|
Feb 07
2024
|
Michael A Metzger Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
146,250
+32.71%
|
-
|
|
Feb 07
2024
|
Pierre Legault |
BUY
Grant, award, or other acquisition
|
Direct |
17,000
+20.73%
|
-
|
|
Feb 07
2024
|
Dennis Podlesak |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+19.34%
|
-
|
|
Feb 07
2024
|
Briggs Morrison |
BUY
Grant, award, or other acquisition
|
Direct |
17,000
+32.8%
|
-
|
|
Feb 07
2024
|
William Meury |
BUY
Grant, award, or other acquisition
|
Direct |
17,000
+20.73%
|
-
|
|
Feb 07
2024
|
Keith Katkin |
BUY
Grant, award, or other acquisition
|
Direct |
17,000
+20.73%
|
-
|
|
Jan 31
2024
|
Keith A. Goldan Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
1,183
+20.2%
|
$20,111
$17.42 P/Share
|
|
Aug 09
2023
|
Briggs Morrison |
SELL
Open market or private sale
|
Direct |
52,855
-74.77%
|
$951,390
$18.27 P/Share
|
|
Aug 09
2023
|
Briggs Morrison |
BUY
Exercise of conversion of derivative security
|
Direct |
52,855
+42.78%
|
$422,840
$8.77 P/Share
|
|
Aug 02
2023
|
William Meury |
SELL
Open market or private sale
|
Direct |
83,000
-36.28%
|
$1,660,000
$20.46 P/Share
|
|
Aug 02
2023
|
William Meury |
BUY
Exercise of conversion of derivative security
|
Direct |
83,000
+26.55%
|
$664,000
$8.15 P/Share
|
|
Jul 31
2023
|
Keith A. Goldan Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
862
+19.81%
|
$15,516
$18.12 P/Share
|
|
Jul 10
2023
|
Briggs Morrison |
SELL
Open market or private sale
|
Direct |
52,855
-74.77%
|
$1,057,100
$20.4 P/Share
|
|
Jul 10
2023
|
Briggs Morrison |
BUY
Exercise of conversion of derivative security
|
Direct |
52,855
+42.78%
|
$422,840
$8.77 P/Share
|
|
Jun 13
2023
|
Keith A. Goldan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
577
-18.0%
|
$12,694
$22.31 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 377K shares |
|---|---|
| Other acquisition or disposition | 1.18K shares |
| Open market or private purchase | 1.25K shares |